Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04343885
Title In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia

prostate cancer

prostate adenocarcinoma



Docetaxel + lutetium Lu 177 vipivotide tetraxetan

Age Groups: adult | senior
Covered Countries

No variant requirements are available.